Intersect ENT (NASDAQ:XENT) PT Lowered to $14.00

Intersect ENT (NASDAQ:XENT) had its target price cut by SVB Leerink from $15.00 to $14.00 in a research report issued to clients and investors on Monday, BenzingaRatingsTable reports. The brokerage currently has a “market perform” rating on the medical equipment provider’s stock. SVB Leerink’s price objective would suggest a potential upside of 8.95% from the stock’s previous close.

A number of other analysts also recently weighed in on the stock. JPMorgan Chase & Co. reduced their price target on shares of Intersect ENT from $28.00 to $18.00 and set an “overweight” rating for the company in a report on Tuesday, May 12th. ValuEngine downgraded shares of Intersect ENT from a “strong-buy” rating to a “buy” rating in a report on Thursday, April 2nd. Piper Sandler reduced their price target on shares of Intersect ENT from $23.00 to $14.00 and set a “neutral” rating for the company in a report on Tuesday, May 12th. BidaskClub downgraded shares of Intersect ENT from a “hold” rating to a “sell” rating in a report on Saturday, May 23rd. Finally, BTIG Research reissued a “hold” rating on shares of Intersect ENT in a report on Wednesday, June 10th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and two have assigned a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $18.14.

NASDAQ XENT opened at $12.85 on Monday. The company has a current ratio of 6.63, a quick ratio of 5.67 and a debt-to-equity ratio of 0.10. The company has a fifty day simple moving average of $12.07 and a 200 day simple moving average of $17.71. The company has a market cap of $393.97 million, a P/E ratio of -8.24 and a beta of 1.12. Intersect ENT has a 1 year low of $5.97 and a 1 year high of $31.46.

Intersect ENT (NASDAQ:XENT) last posted its quarterly earnings data on Monday, May 11th. The medical equipment provider reported ($0.54) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.44) by ($0.10). The firm had revenue of $19.83 million for the quarter, compared to the consensus estimate of $19.70 million. Intersect ENT had a negative return on equity of 43.72% and a negative net margin of 48.61%. Equities research analysts forecast that Intersect ENT will post -1.76 EPS for the current fiscal year.

Several large investors have recently added to or reduced their stakes in XENT. FMR LLC lifted its holdings in shares of Intersect ENT by 1,863.8% during the 1st quarter. FMR LLC now owns 632,451 shares of the medical equipment provider’s stock worth $20,334,000 after acquiring an additional 600,246 shares during the period. Rhumbline Advisers increased its position in shares of Intersect ENT by 0.9% during the 4th quarter. Rhumbline Advisers now owns 41,580 shares of the medical equipment provider’s stock worth $1,035,000 after purchasing an additional 388 shares in the last quarter. Swiss National Bank increased its position in shares of Intersect ENT by 2.9% during the 4th quarter. Swiss National Bank now owns 60,300 shares of the medical equipment provider’s stock worth $1,501,000 after purchasing an additional 1,700 shares in the last quarter. Victory Capital Management Inc. increased its position in shares of Intersect ENT by 36.9% during the 4th quarter. Victory Capital Management Inc. now owns 6,778 shares of the medical equipment provider’s stock worth $169,000 after purchasing an additional 1,827 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its position in shares of Intersect ENT by 2.0% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 190,496 shares of the medical equipment provider’s stock worth $4,744,000 after purchasing an additional 3,817 shares in the last quarter. 87.70% of the stock is owned by institutional investors.

About Intersect ENT

Intersect ENT, Inc, a drug delivery company, researches and develops products for the treatment of patients with ear, nose, and throat conditions in the United States. The company offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses.

Further Reading: The Discount Rate – What You Need to Know

Analyst Recommendations for Intersect ENT (NASDAQ:XENT)

Receive News & Ratings for Intersect ENT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT and related companies with MarketBeat.com's FREE daily email newsletter.